Lineage Cell Therapeutics (LCTX) Income from Non-Controlling Interests (2010 - 2026)
Lineage Cell Therapeutics' (LCTX) quarterly Income from Non-Controlling Interests came in at $23000.0 in Q1 2026, up 675.0% year-on-year from $2967.7 in Q1 2025, and down 43.9% quarter-over-quarter from $41000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Income from Non-Controlling Interests (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Income from Non-Controlling Interests history runs 17 years deep, the most recent figure standing at $23000.0 for Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests rose 675.0% year-over-year to $23000.0 in Q1 2026; TTM through Mar 2026 was $193000.0, a 394.87% increase from a year earlier, with the FY2025 full-year figure at $166000.0, up 514.81% from the prior year.
- Income from Non-Controlling Interests retreated to $23000.0 in Q1 2026 per LCTX's latest filing, from $41000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $100000.0 in Q2 2025 and bottomed at -$48000.0 in Q3 2023.
- The 5-year median for Income from Non-Controlling Interests is -$4000.0 (2025), against an average of $8411.8.
- Across the five-year window, Income from Non-Controlling Interests slumped 433.33% in 2023 and soared 869.23% in 2025, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$8000.0 in 2022, then jumped by 862.5% to $61000.0 in 2023, then plunged by 62.3% to $23000.0 in 2024, then jumped by 78.26% to $41000.0 in 2025, then slumped by 43.9% to $23000.0 in 2026.
- Per Business Quant, the three latest LCTX Income from Non-Controlling Interests figures stand at $23000.0 (Q1 2026), $41000.0 (Q4 2025), and $29000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 251.15 Mn | 188.44 Mn | 1.73 Mn | 23,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23,000.00 |
| Dec 31, 2025 | 41,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | -13,000.00 |
| Mar 31, 2024 | -16,000.00 |
| Dec 31, 2023 | 61,000.00 |
| Sep 30, 2023 | -48,000.00 |
| Jun 30, 2023 | 26,000.00 |
| Mar 31, 2023 | -32,000.00 |
| Dec 31, 2022 | -8,000.00 |
| Sep 30, 2022 | -47,000.00 |
| Jun 30, 2022 | -19,000.00 |
| Mar 31, 2022 | -6,000.00 |
| Dec 31, 2021 | -200,000.00 |
| Sep 30, 2021 | -11,000.00 |
| Jun 30, 2021 | -8,000.00 |